Xofluza

Influenza, Influenza, Influenza + 2 more
Treatment
20 Active Studies for Xofluza

What is Xofluza

Baloxavir marboxilThe Generic name of this drug
Treatment SummaryBaloxavir marboxil is an antiviral drug used to treat influenza A and B infections. It was approved for use in Japan in 2018 and by the FDA in October of the same year. Baloxavir marboxil works differently than other antiviral drugs used to treat influenza infections and can be prescribed to adults and children over the age of 12 who have been experiencing symptoms for no more than 48 hours.
Xofluzais the brand name
image of different drug pills on a surface
Xofluza Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Xofluza
Baloxavir marboxil
2018
6

Effectiveness

How Xofluza Affects PatientsBaloxavir marboxil is a medication used to treat influenza virus infections. It works by blocking the virus from reproducing, and has been shown to reduce viral levels and improve survival rates in mice. The drug's effects can be seen within 24 hours of administration, and the effectiveness increases with higher doses.
How Xofluza works in the bodyThe influenza virus needs a special enzyme to replicate and produce viral mRNA. This enzyme is made up of three proteins, which all have different roles. The first protein binds to the host cell pre-mRNA and cuts it, which provides a primer for the other proteins. After taking baloxavir marboxil, it is broken down into its active form, baloxavir. Baloxavir then blocks the PA protein, which stops the influenza virus from replicating and spreading. Baloxavir works on a highly conserved region of the PA protein, but it can still become resistant to it if the protein has certain

When to interrupt dosage

The prescribed quantity of Xofluza is governed by the specified condition. The dosage of the medication varies in accordance with the method of administration (e.g. Tablet, film coated or Tablet, film coated - Oral) as presented in the table below.
Condition
Dosage
Administration
Influenza
, 40.0 mg, 20.0 mg, 40.0 mg/mL, 80.0 mg
, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet - Oral, Tablet, Granule, for solution - Oral, Granule, for solution
Influenza
, 40.0 mg, 20.0 mg, 40.0 mg/mL, 80.0 mg
, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet - Oral, Tablet, Granule, for solution - Oral, Granule, for solution
Healthy State
, 40.0 mg, 20.0 mg, 40.0 mg/mL, 80.0 mg
, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet - Oral, Tablet, Granule, for solution - Oral, Granule, for solution
Influenza
, 40.0 mg, 20.0 mg, 40.0 mg/mL, 80.0 mg
, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet - Oral, Tablet, Granule, for solution - Oral, Granule, for solution
Risk of Complications
, 40.0 mg, 20.0 mg, 40.0 mg/mL, 80.0 mg
, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet - Oral, Tablet, Granule, for solution - Oral, Granule, for solution

Warnings

Xofluza has one contraindication; it should not be utilized in combination with any of the problems specified in the following table.Xofluza Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Baloxavir Marboxil may interact with Pulse Frequency
There are 12 known major drug interactions with Xofluza.
Common Xofluza Drug Interactions
Drug Name
Risk Level
Description
Adenovirus type 7 vaccine live
Moderate
The therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Baloxavir marboxil.
Anthrax vaccine
Moderate
The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Baloxavir marboxil.
BCG vaccine
Moderate
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Baloxavir marboxil.
Bacillus calmette-guerin substrain connaught live antigen
Moderate
The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Baloxavir marboxil.
Bacillus calmette-guerin substrain russian BCG-I live antigen
Moderate
The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Baloxavir marboxil.
Xofluza Toxicity & Overdose RiskTests with rats have found that the most toxic dose of baloxavir is greater than 2000 mg/kg. In human trials, doses up to 80mg have been administered without any major safety concerns. In case of an overdose, patients should be monitored closely and provided with general supportive care. There is no specific antidote, and dialysis is unlikely to be effective since the drug binds to proteins in the blood.
image of a doctor in a lab doing drug, clinical research

Xofluza Novel Uses: Which Conditions Have a Clinical Trial Featuring Xofluza?

Zero active clinical trials are presently underway to determine the potential of Xofluza in treating Influenza.
Condition
Clinical Trials
Trial Phases
Influenza
0 Actively Recruiting
Risk of Complications
0 Actively Recruiting
Healthy State
0 Actively Recruiting
Influenza
29 Actively Recruiting
Not Applicable, Phase 4, Phase 2, Phase 1, Phase 3
Influenza
0 Actively Recruiting

Xofluza Reviews: What are patients saying about Xofluza?

5Patient Review
2/15/2020
Xofluza for The Flu
I got the flu on Thursday evening and felt awful. I could hardly walk. went to see a doctor who prescribe this medication, which I picked up from Walmart pharmacy. By 4pm Friday, I had no flu symptoms!
5Patient Review
2/20/2020
Xofluza for The Flu
I took this drug 24 hours after start of symptoms after testing positive for Influenza A. Within 24 hours I felt much better. My fever was gone and I didn't seem to have any side effects.
5Patient Review
2/25/2020
Xofluza for The Flu
I got the flu really bad, but after taking this medication I was feeling so much better just a day later.
5Patient Review
2/22/2020
Xofluza for The Flu
I took Xofluza yesterday when I was feeling really sick, and this morning I woke up feeling SO much better.
5Patient Review
10/29/2022
Xofluza for The Flu
Xofluza really helped me turn the corner on my bout with the flu. I was feeling awful but after taking it as directed, I woke up feeling so much better.
5Patient Review
11/17/2021
Xofluza for The Flu
I got the flu but this treatment helped me recover quickly. I'm feeling much better now and it's only been a day since I started taking it.
5Patient Review
7/22/2020
Xofluza for The Flu
I felt better very soon after taking this, and it was much easier to take than Tamiflu.
5Patient Review
1/3/2020
Xofluza for The Flu
I got the flu even though I got the flu shot back in October. Xofluza was prescribed to me, but it didn't take effect until a few days later. The effects were worth the wait though; I felt so much better after taking it.
5Patient Review
2/8/2020
Xofluza for The Flu
I was diagnosed with the flu and this treatment had me feeling better in just two days.
5Patient Review
2/24/2020
Xofluza for The Flu
I was feeling awful with the flu, but after taking Xofluxa I felt much better within just a few hours. Most of my symptoms were gone within 24 hours, which is pretty impressive given how miserable I was feeling beforehand.
3.3Patient Review
1/23/2020
Xofluza for The Flu
I was able to find a coupon which made this more affordable, but I still missed three days of work. It's hard to say how effective this was because I don't know how bad the sickness would've been without it.
2.3Patient Review
11/27/2019
Xofluza for The Flu
Unfortunately, this medication had terrible results for me. I experienced every single bad reaction that was listed on the packaging and more. I contacted the drug company but didn't get my money back. All in all, I was sick for over three weeks and it could take up to six weeks total.
2.3Patient Review
1/22/2020
Xofluza for The Flu
I got this for my sons and me after we were diagnosed with Flu A, but it didn't work at all. My parents, who also had Flu A, used Tamiflu and felt better within a few days. We were still sick 10 days later.
2.3Patient Review
2/2/2020
Xofluza for The Flu
While Xofluza may have shortened the length of my flu, the side effects were incredibly unpleasant. I felt so dry that it was uncomfortable to swallow or breathe. My mouth was painfully dry. I would not recommend this medication to others.
1Patient Review
12/22/2019
Xofluza for The Flu
I was very hesitant to try this new medication when I woke up with the flu, but within a few hours I could tell a significant difference. My body aches were much better and all my symptoms were less severe. That being said, I did have some bad loose bowels and awful headaches. But I can't say for sure if those were side effects of the medication or not. Either way, I'm on day four now and feeling much improved.
1Patient Review
1/11/2020
Xofluza for The Flu
I was diagnosed with the flu on Thursday, January 2nd. I got a celestone shot and Xofluza, and within 24 hours I was feeling much better. My fever only dropped to a very low grade, but all of my other symptoms (slight cough excluded) were gone.
1Patient Review
2/6/2020
Xofluza for The Flu
I was diagnosed with the flu about 24-hours after first onset of symptoms. I took both pills at once as directed, and saw no benefit whatsoever.
1Patient Review
10/10/2019
Xofluza for The Flu
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about xofluza

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How effective is Xofluza?

"In adolescent patients, XOFLUZA provides 42% faster relief from flu symptoms than placebo."

Answered by AI

Do I need a prescription for Xofluza?

"This medication is used to either treat or prevent the flu in individuals who are at least 12 years old. It is most effective if taken within 48 hours of the first flu symptoms appearing."

Answered by AI

What symptoms does Xofluza treat?

"If you have started experiencing flu symptoms within the last 48 hours, baloxavir marboxil can be taken as an antiviral medication to help lessen the symptoms. These symptoms may include a stuffy nose, cough, sore throat, fever or chills, aches, and tiredness. In some cases, it has been shown to shorten the overall recovery time by one or two days."

Answered by AI

How is Xofluza different from Tamiflu?

"Xofluza is more effective than Tamiflu because it stops the influenza virus from being able to reproduce. Currently, Xofluza is only approved to treat the flu, not prevent it. Xofluza must be started within 48 hours of first feeling symptoms in order for it to work."

Answered by AI

How long does it take for Xofluza to work?

"If you take a dose of Xofluza, it will start working against the flu virus within 4 hours. In people who have taken Xofluza to treat the flu, the majority feel better within 2 days. If you don't start feeling better within 2 days of taking Xofluza, or if your symptoms get worse, call your doctor."

Answered by AI

What is Xofluza used for?

"This medication is used to treat influenza within 48 hours of symptom onset in healthy adults and children 5 years of age and older, as well as adults and children 12 years of age and older who are high-risk for developing complications from the flu."

Answered by AI

Is Tamiflu a Xofluza?

"Xofluza works by stopping the influenza virus from replicating, while Tamiflu works by countering the effects of the virus. Xofluza is only effective when taken within 48 hours of the onset of symptoms, while Tamiflu can be taken up to five days after the onset of symptoms."

Answered by AI

Clinical Trials for Xofluza

Image of National Institutes of Health Clinical Center in Bethesda, United States.

BPL-1357 for Flu

18 - 55
All Sexes
Bethesda, MD
Background: Influenza (flu) infections are a serious global health threat. Each year, between 3 and 5 million people get the flu, and up to 500,000 die from it. Current vaccines protect against seasonal flus, but broader vaccines are needed to protect against potential flu pandemics. Objective: To test an experimental flu vaccine. Eligibility: Healthy people aged 18 to 55 years. Design: The study will last 5 to 8 months and has 2 phases, A and B. The study vaccine will be given either as a shot in the arm or as a nasal spray. Participants will receive 1 of 3 combinations: (1) study vaccine in the nose and placebo in the arm; (2) placebo in the nose and study vaccine in the arm; or (3) placebo in the nose and placebo in the arm. A placebo is just like the real vaccine but contains no active ingredients. Phase A: Participants will have 5 clinic visits over 56 days. They will receive a shot and a nasal spray at 2 of the visits, 28 days apart. At each visit, they will have a physical exam, with tests of their blood, urine, and nasal secretions. They will check their temperature at home and record any symptoms for 7 days after each vaccine. Phase B: Participants will stay in the hospital for at least 9 days. They will be infected with a flu virus. They will provide blood, urine, and nasal fluid samples. They will have tests of their heart function. They will remain in the hospital until they test negative for the flu 2 days in a row. They will have 2 follow-up visits, 4 and 8 weeks after leaving the hospital.
Phase 2
Waitlist Available
National Institutes of Health Clinical Center (+1 Sites)Luca T Giurgea, M.D.
Image of Vanderbilt University Medical Center in Nashville, United States.

High vs. Standard Dose Influenza Vaccines for Flu

18+
All Sexes
Nashville, TN
This will be a follow-up study to the "Comparison of High Dose vs. Standard Dose Influenza Vaccine in Lung Allograft Recipient" study (DMID Protocol Number 22-0014) at Vanderbilt University Medical Center. Lung transplantation is a life-saving therapy for patients with advanced lung disease, and is also associated with an improvement in quality of life. However, due to the need for life-long immunosuppression to prevent acute cellular rejection and chronic lung allograft dysfunction ("chronic rejection"), lung transplant recipients are at risk for developing major infections. In fact, one-year survival is 85%, with infection being the leading cause of death within the first year post-transplant. We will conduct a follow-up phase II, randomized, double-blind trial to assess the impact of subsequent administration of two doses of HD-IIV compared to two doses of SD-IIV among lung recipients during the early post-transplant period. Demonstration of improved immunogenicity from two doses of HD-IIV over consecutive influenza seasons would provide potential broad benefit in reducing influenza disease and its associated complications in lung transplant recipients. Moreover, studying vaccine immunogenicity and safety in the same participants over consecutive years can provide insight into the influence of immunosuppression levels and allograft aging on vaccine-mediated immune modulation. This proposed study design will contribute significantly to influenza vaccination guidance and policy for the highly vulnerable lung transplant population. This proposed study is designed to address several key knowledge gaps in vaccine-mediated protection of lung transplant recipients against influenza: * Is there increased immunogenicity with administration of one or two doses of HD-IIV or SD-IIV in the subsequent season compared to two doses of HD-IIV or SD-IIV in the first season? * What is the durability of the humoral and cellular immune response between influenza seasons and does two doses of HD-IIV or SD-IIV sustain higher HAI titers compared to two doses of HD-IIV or SD-IIV in the first season? * What is the impact of maintenance immunosuppression levels on influenza vaccine immunogenicity within the same participant? * Will the optimal immunogenic vaccination strategy be associated with an acceptable long-term safety profile over successive influenza seasons, including injection-site and systemic reactions, allosensitization, and organ rejection?
Phase 2
Recruiting
Vanderbilt University Medical CenterNatahsa Halasa, MD, MPH
Image of Altasciences Inc - Kansas City in Overland Park, United States.

VNT-101 for Safety and Tolerability Study

18 - 59
All Sexes
Overland Park, KS
A randomized, double-blind, placebo-controlled Phase 1 study conducted at a single center with approximately 78 healthy adults aged 18-59 years. Part 1 Single Ascending Dose (SAD) will enroll 48 participants into six cohorts (S1-S6) to receive single oral doses of VNT-101 (100-1500 mg) or placebo under fasting or fed (S5 only) conditions. Part 2 Multiple Ascending Dose (MAD) will enroll 30 participants into three cohorts (M1-M3) to receive multiple oral doses of VNT-101 (250-750 mg BID Days 1-5, QD Day 6) or placebo under fasting conditions. Dose escalation in both parts will proceed after Protocol Safety Review Team (PSRT) review. The primary objective for Part 1 is to evaluate the safety and tolerability of single ascending oral (SAD) doses of VNT-101 in healthy adult participants under either fasting or fed conditions. The primary objective for part 2 is to evaluate the safety and tolerability of multiple ascending oral (MAD) doses of VNT-101 in healthy adult participants.
Phase 1
Recruiting
Altasciences Inc - Kansas City
Have you considered Xofluza clinical trials? We made a collection of clinical trials featuring Xofluza, we think they might fit your search criteria.Go to Trials
Image of Saint Louis University Center for Vaccine Development in St Louis, United States.

A/Texas for Flu

18 - 45
All Sexes
St Louis, MO
This is a research study to understand what happens when a person is infected with influenza ("flu") and how the body controls the infection. Healthy participants (challenge) will be infected with a strain of flu (H3N2), and followed to see what symptoms occur and when they occur. Blood will be drawn and nasopharyngeal (NP) swabs will be collected before participants are infected to understand if having antibodies can protect participants from flu infection or lead to a milder flu illness. Blood will also be drawn and NP swabs collected after participants are infected to understand how and when the body's immune response to flu occurs. Participants will also breathe through a device for virus collection every other day. Participants will be screened during one or more visits and will stay in the inpatient challenge unit for at least 10 days, maybe longer. Participants will complete a FLU PRO Diary Card daily. Blood will be drawn before the challenge and on Days 2, 4, and 8 while in the inpatient unit. NP samples will be taken every day to check for viruses and on certain days, immune responses such as antibodies. If on Day 8 (7 days after the challenge) the participant still has flu virus, medicine will be offered to treat the flu and the participant will be asked to stay in the challenge unit until NP swabs are negative for 2 consecutive days. Once the participant is discharged from the challenge unit, they will be asked to return to the clinic for 3 more visits. At the end of the study will be a final phone call.
Phase 1
Waitlist Available
Saint Louis University Center for Vaccine DevelopmentDaniel F. Hoft, MD, PhD
Image of Emory University Hospital Clinical Research Network in Atlanta, United States.

Influenza Virus for Influenza

18 - 49
All Sexes
Atlanta, GA
This study is designed to help us better understand how the immune system responds to the flu and how flu is transmitted in the environment. The ultimate goal is to develop better vaccines and drugs to protect against or fight the flu. This study will describe how the body's immune system responds to the flu virus during and after infection and how the flu virus is transmitted in the environment. The study will use a flu virus called A/Texas/71/2017 (H3N2), clade 3C3a produced specifically for clinical research in controlled conditions. The study will also assess the safety of the H3N2 influenza challenge in healthy participants. Mild to moderate symptoms are expected based on previous studies with this strain of influenza. Study volunteers will be recruited and screened from the general population of metro Atlanta through advertisements or identified from a database of research participants who have previously agreed to be contacted for future research studies. Participants will provide written consent before study participation. Up to 200 healthy adults, 18-49 years old, will be screened for participation. Eligible participants will take part in the study over 5 months. Enrolled participants will be admitted to Emory University Hospital during which time they will receive the influenza virus in the form of a spray in the nose or exposure to infected participants followed by an 8-12 day inpatient stay for observation. Follow-up outpatient visits will take place at the Hope Clinic of the Emory Vaccine Center. Participants will receive compensation (pro-rated for all visits completed) for their time and effort. There will be no costs to participants as a result of being in the study.
Phase 1
Recruiting
Emory University Hospital Clinical Research Network (+1 Sites)Nadine Rouphael, MD
Have you considered Xofluza clinical trials? We made a collection of clinical trials featuring Xofluza, we think they might fit your search criteria.Go to Trials
Image of Loma Linda University Medical Center Troesh Medical Campus in Loma Linda, United States.

Endotracheal Suctioning for Procedural Pain

18+
All Sexes
Loma Linda, CA
The goal of this experimental study is to understand if endotracheal tube (ETT) suctioning increases pain and causes stress on the body in intubated adult ICU patients. These patients are already on ventilators, which means they need suctioning to keep their airways clear, but this procedure may be uncomfortable and cause stress. The main questions this study aims to answer are: Does ETT suctioning raise pain levels as measured by the Critical-Care Pain Observation Tool (CPOT)? Does ETT suctioning increase certain chemicals in the blood (hypoxanthine, xanthine, and uric acid) that show stress and lack of oxygen in the body? Researchers will compare patients who have ETT suctioning (intervention group) with those who do not have suctioning during the study period (control group) to see if there are differences in pain and blood markers of stress. Participants will: Have pain measured before and after suctioning using the CPOT. Have blood samples taken from an existing line at three time points: 5 minutes before, 5 minutes after, and 30 minutes after suctioning. Provide demographic information (like age, gender, and diagnosis) from medical records. This research will help improve how pain is managed for ICU patients who cannot speak for themselves, potentially leading to better pain relief methods in the future.
Recruiting
Has No Placebo
Loma Linda University Medical Center Troesh Medical CampusElizabeth Johnston Taylor, PhD, FAAN
Image of Research Institute of McGill University Health Centre in Montréal, Canada.

COVID-19 Booster + Flu Vaccine for Immunocompromised People

18+
All Sexes
Montréal, Canada
The goal of this pragmatic embedded open-label, 2 x 2 factorial phase II randomized controlled trial is to evaluate strategies to improve COVID-19 booster and influenza vaccine immunogenicity in people living with immunocompromising conditions (PLIC). The main questions it aims to answer are: 1. Is co-administration of seasonal inactivated influenza vaccine (IIV) with the most up-to-date recommended COVID-19 booster dose non-inferior in inducing a 1-month peak protective humoral response against COVID-19, compared to a strategy of sequential administration of COVID-19 booster dose followed by seasonal IIV given one month later? 2. Is the administration of the most up-to-date recommended COVID-19 booster doses at 3-month intervals superior at maintaining a longer term protective humoral immune response, compared to booster doses administered at 6-month intervals? Researchers will compare (1) COVID-19 and Influenza vaccines administered at Day 0 + COVID-19 Booster at a 3-month interval, (2) COVID-19 vaccine administered at Day 0 and Influenza vaccine administered at Day 28 + COVID-19 Booster at a 3-month interval, (3) COVID-19 and Influenza vaccines administered at Day 0 + COVID-19 Booster at a 6-month interval, and (4) COVID-19 vaccine administered at Day 0 and Influenza vaccine administered at Day 28 + COVID-19 Booster at a 6-month interval to see if median neutralization capacity of patient sera is non-inferior in the co- vs. sequential administration arms at 1-month after the initial COVID-19 booster and superior in the 3-month interval arms vs. the 6-month interval arms at 12 months after the initial COVID-19 booster. These outcomes will also be compared at 2-months for question 1 and 6-months for question 2. People living with immunocompromising conditions who take part in the trial will have blood samples drawn to verify immune response, be monitored for changes in clinical events and therapies, and complete questionnaires to verify adverse effects, quality of life and economic impact.
Phase 2
Recruiting
Research Institute of McGill University Health Centre (+1 Sites)
Image of Kaiser Permanente Northern California in Pleasanton, United States.

Nudge Communication for Flu Vaccination

18+
All Sexes
Pleasanton, CA
In randomized clinical trials and observational studies, influenza vaccination is effective in reducing influenza-related illness and hospitalizations and potentially cardiovascular (CV) events and mortality in select populations. However, the potential population-level benefit of influenza vaccination is limited by its uptake. Novel implementation strategies to improve vaccination uptake are needed. KP VACCINATE is a multicenter, sequential, individual-level randomized controlled implementation trial examining the effectiveness of a CV-focused nudging communication vs. usual care communication on influenza vaccination uptake among Kaiser Permanente Northern California (KPNC) and Kaiser Permanente Mid Atlantic States (KPMAS) eligible members during the 2024-2025 influenza season.
Waitlist Available
Has No Placebo
Kaiser Permanente Northern California (+1 Sites)Ankeet Bhatt, MD
Image of Rush University in Chicago, United States.

Science Communication Training for Vaccine Hesitancy

18 - 99
All Sexes
Chicago, IL
Dime La VerDAD is an innovative social media capacity-building program that empowers promotores de salud to debunk vaccine misinformation through the use of personal narratives on social media. The core of the implementation strategy consists of augmenting training and self-efficacy for natural community champions, "promotores de salud" from the Hispanic community as trusted messengers to debunk vaccination misinformation. The study will leverage existing community relationships in Chicago and a first of its kind misinformation curriculum to debunk misinformation in communities served by participating promotores de salud. Dime La VerDAD (Verify, Debunk, and Disseminate) is an innovative social media capacity-building program based on theoretical frameworks related to health communication that empowers promotores de salud to debunk vaccine misinformation through the use of personal narratives on social media. This mixed methods study will use a rigorous stepped wedge design to 1) deliver a scalable program of science communicators using an adapted curriculum grounded in infodemiology, 2) evaluate how debunking misinformation is perceived on social media, and 3) discern how use of personal narratives to enhance science communication can lead to changes in opinions and behavior (vaccination rates) about COVID and influenza vaccines among Chicago's predominantly Hispanic communities.
Recruiting
Has No Placebo
Rush University (+3 Sites)Marina DelRios, MD
Have you considered Xofluza clinical trials? We made a collection of clinical trials featuring Xofluza, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security